Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912891270> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2912891270 abstract "344 Background: Nal-IRI plus 5-FU/LV has demonstrated efficacy in mPDAC pts who previously received gemcitabine-based therapy in the pivotal NAPOLI-1 trial. Real-world data are helpful to measure the clinical outcomes and safety profile of this regimen in daily practice setting. Methods: Between January 2017 and April 2018, a Named Patient Program (NPP) was activated to provide controlled, pre-approval access of nal-IRI in Korea. This analysis is multicenter retrospective study for patients who received nal-IRI plus 5-FU/LV under the NPP. Results: A total of 86 patients entered into this NPP among 10 Korean institutions. Median age was 61 years (range, 37-79) and 52 pts (60%) were male. Liver (n=49, 57%), peritoneum (30, 35%), and lung (27, n=31%) were the most common metastatic sites. All patients had ECOG performance status 0-1 and previously received gemcitabine-based therapy. Prior to nal-IRI plus 5-FU/LV, 35 (41%) and 51 (59%) patients received <2 and ≥ 2 lines of chemotherapy for unresectable/metastatic disease, respectively. Best response was complete response (n=2, 2%), partial response (7, 8%), stable disease (38, 44%), and progressive disease (32, 37%), indicating overall response rates of 10% and disease control rate of 55%. With median follow-up duration of 6.4 months, median progression-free survival (PFS) was 3.5 months (95% CI, 1.3-5.7) and median overall survival (OS) was not yet reached. The 6-month PFS and OS rates were 37.5% and 65.1%, respectively. Most common grade 3-4 toxicities were neutropenia (n=32, 37%), nausea (9, 10%), vomiting (8, 9%), anemia (7, 8%), and diarrhea (4, 5%). Febrile neutropenia occurred in 7 patients (8%). Conclusions: Nal-IRI plus 5-FU/LV was well tolerated and effective for mPDAC patients who progressed on gemcitabine-based therapy. Despite heavily pretreated patients were included, efficacy and safety outcomes in our cohort were consistent with the results of previous NAPOLI-1 trial." @default.
- W2912891270 created "2019-02-21" @default.
- W2912891270 creator A5000487712 @default.
- W2912891270 creator A5025356855 @default.
- W2912891270 creator A5026351538 @default.
- W2912891270 creator A5030219026 @default.
- W2912891270 creator A5034731588 @default.
- W2912891270 creator A5035182573 @default.
- W2912891270 creator A5044558998 @default.
- W2912891270 creator A5045587524 @default.
- W2912891270 creator A5050625196 @default.
- W2912891270 creator A5059766169 @default.
- W2912891270 creator A5066759908 @default.
- W2912891270 creator A5071276908 @default.
- W2912891270 creator A5071819927 @default.
- W2912891270 creator A5075932421 @default.
- W2912891270 creator A5082143898 @default.
- W2912891270 creator A5090754319 @default.
- W2912891270 date "2019-02-01" @default.
- W2912891270 modified "2023-10-16" @default.
- W2912891270 title "Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG)." @default.
- W2912891270 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.344" @default.
- W2912891270 hasPublicationYear "2019" @default.
- W2912891270 type Work @default.
- W2912891270 sameAs 2912891270 @default.
- W2912891270 citedByCount "1" @default.
- W2912891270 countsByYear W29128912702020 @default.
- W2912891270 crossrefType "journal-article" @default.
- W2912891270 hasAuthorship W2912891270A5000487712 @default.
- W2912891270 hasAuthorship W2912891270A5025356855 @default.
- W2912891270 hasAuthorship W2912891270A5026351538 @default.
- W2912891270 hasAuthorship W2912891270A5030219026 @default.
- W2912891270 hasAuthorship W2912891270A5034731588 @default.
- W2912891270 hasAuthorship W2912891270A5035182573 @default.
- W2912891270 hasAuthorship W2912891270A5044558998 @default.
- W2912891270 hasAuthorship W2912891270A5045587524 @default.
- W2912891270 hasAuthorship W2912891270A5050625196 @default.
- W2912891270 hasAuthorship W2912891270A5059766169 @default.
- W2912891270 hasAuthorship W2912891270A5066759908 @default.
- W2912891270 hasAuthorship W2912891270A5071276908 @default.
- W2912891270 hasAuthorship W2912891270A5071819927 @default.
- W2912891270 hasAuthorship W2912891270A5075932421 @default.
- W2912891270 hasAuthorship W2912891270A5082143898 @default.
- W2912891270 hasAuthorship W2912891270A5090754319 @default.
- W2912891270 hasConcept C121608353 @default.
- W2912891270 hasConcept C126322002 @default.
- W2912891270 hasConcept C141071460 @default.
- W2912891270 hasConcept C143998085 @default.
- W2912891270 hasConcept C2776694085 @default.
- W2912891270 hasConcept C2778336483 @default.
- W2912891270 hasConcept C2778822529 @default.
- W2912891270 hasConcept C2780258809 @default.
- W2912891270 hasConcept C2780259306 @default.
- W2912891270 hasConcept C2780739268 @default.
- W2912891270 hasConcept C2781413609 @default.
- W2912891270 hasConcept C526805850 @default.
- W2912891270 hasConcept C71924100 @default.
- W2912891270 hasConcept C90924648 @default.
- W2912891270 hasConceptScore W2912891270C121608353 @default.
- W2912891270 hasConceptScore W2912891270C126322002 @default.
- W2912891270 hasConceptScore W2912891270C141071460 @default.
- W2912891270 hasConceptScore W2912891270C143998085 @default.
- W2912891270 hasConceptScore W2912891270C2776694085 @default.
- W2912891270 hasConceptScore W2912891270C2778336483 @default.
- W2912891270 hasConceptScore W2912891270C2778822529 @default.
- W2912891270 hasConceptScore W2912891270C2780258809 @default.
- W2912891270 hasConceptScore W2912891270C2780259306 @default.
- W2912891270 hasConceptScore W2912891270C2780739268 @default.
- W2912891270 hasConceptScore W2912891270C2781413609 @default.
- W2912891270 hasConceptScore W2912891270C526805850 @default.
- W2912891270 hasConceptScore W2912891270C71924100 @default.
- W2912891270 hasConceptScore W2912891270C90924648 @default.
- W2912891270 hasLocation W29128912701 @default.
- W2912891270 hasOpenAccess W2912891270 @default.
- W2912891270 hasPrimaryLocation W29128912701 @default.
- W2912891270 hasRelatedWork W1965958893 @default.
- W2912891270 hasRelatedWork W2011990520 @default.
- W2912891270 hasRelatedWork W2023991085 @default.
- W2912891270 hasRelatedWork W2065498827 @default.
- W2912891270 hasRelatedWork W2477222816 @default.
- W2912891270 hasRelatedWork W2533791265 @default.
- W2912891270 hasRelatedWork W2599910524 @default.
- W2912891270 hasRelatedWork W2811271347 @default.
- W2912891270 hasRelatedWork W3202939723 @default.
- W2912891270 hasRelatedWork W3210188041 @default.
- W2912891270 isParatext "false" @default.
- W2912891270 isRetracted "false" @default.
- W2912891270 magId "2912891270" @default.
- W2912891270 workType "article" @default.